Company: CDLX
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001666071-25-000126
Chunk: 102

Company: Cardlytics, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Item 1
Chunk 102
---
-average common shares outstanding, basic and diluted52,750 49,056 52,309 46,168 

See notes to the condensed consolidated financial statements4

CARDLYTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)

(Amounts in thousands)

 Three Months EndedJune 30,Six Months EndedJune 30, 2025202420252024Net Loss$(9,283)$(4,257)$(22,565)$(28,532)Other Comprehensive (Loss) Income:Foreign currency translation adjustments(4,874)(94)(7,229)486 Total Comprehensive Loss$(14,157)$(4,351)$(29,794)$(28,046)

See notes to the condensed consolidated financial statements5

CARDLYTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (UNAUDITED)

(Amounts in thousands)

Six Months Ended June 30, 2025:

  AdditionalPaid-InCapitalAccumulatedOtherComprehensive Income (Loss)AccumulatedDeficitTotal Common Stock SharesAmountBalance – December 31, 202451,257 $10 $1,366,958 $3,601 $(1,300,576)$69,993 Stock-based compensation— — 18,060 — — 18,060 Settlement of restricted stock1,474 — — — — — Issuance of common stock pursuant to the 2018 ESPP (as defined below)263 — 447 — — 447 Other comprehensive loss— — — (7,229)— (7,229)Net Loss— — — — (22,565)(22,565)Balance – June 30, 202552,994 $10 $1,385,465 $(3,628)$(1,323,141)$58,706 

Three Months Ended June 30, 2025:

  AdditionalPaid-InCapitalAccumulatedOtherComprehensive IncomeAccumulatedDeficitTotal Common Stock SharesAmountBalance – March 31, 202552,175 $10 $1,376,692 $1,246 $(1,313,858)$64,090 Stock-based compensation— — 8,326